Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease

Approved as a Long-Term Enzyme Replacement Therapy in Combination with Miglustat for All Adults Living with Late-Onset Pompe Disease CHMP Opinion for Miglustat, the Oral Enzyme Stabilizer... | March 27, 2023

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Andrew Faughnan ,Johnf Crowley ,Diana Moore ,Bradley Campbell ,Twitter ,Globenewswire Inc ,European Commission ,Amicus Therapeutics Inc ,Amicus Therapeutics ,Linkedin ,Global Corporate Communications ,Committee For Medicinal Products Human Use ,Method Of Administration ,Long Term Enzyme Replacement Therapy ,All Adults Living ,Late Onset Pompe ,Oral Enzyme Stabilizer Component ,Medicinal Products ,Human Use ,Executive Chairman ,Chief Executive Officer ,Important Safety ,Private Securities Litigation Reform Act ,Pompe Disease ,Annual Report ,Nc Stock Exchange ,News ,Information ,Press Release ,Approved ,Us ,Nzyme ,Replacement ,Combination ,Ith ,Miglustat ,Or ,Wall ,Adults ,Diving ,Pompe ,Disease ,Thmp ,Opinion ,The ,Mural ,Nzyme Fold Us03152w1099 ,